Research programme: hyperphosphataemia therapy - Acologix

Drug Profile

Research programme: hyperphosphataemia therapy - Acologix

Alternative Names: AC-200; Matrix extracellular phosphoglycoprotein - Acologix; MEPE; Phosphatonin

Latest Information Update: 16 Oct 2009

Price : $50

At a glance

  • Originator Acologix; University College London
  • Developer Acologix
  • Class Glycoproteins
  • Mechanism of Action Extracellular matrix protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Hyperphosphataemia

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in a rat model of chronic kidney failure released by Acologix
  • 22 Jun 2006 Phosphatonin (AC 200) has been licensed to Toray Industries in Japan
  • 16 Nov 2005 Preclinical data from a media release have been added to the Metabolic disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top